Literature DB >> 11683929

A pilot study to determine the effectiveness of garlic oil capsules in the treatment of dyspeptic patients with Helicobacter pylori.

C A McNulty1, M P Wilson, W Havinga, B Johnston, E A O'Gara, D J Maslin.   

Abstract

BACKGROUND: Resistance of Helicobacter pylori to clarithromycin and metronidazole is now found worldwide. Steam-distilled garlic oil has in vitro activity against H. pylori and may be a useful alternative treatment strategy.
MATERIALS AND METHODS: In this pilot study dyspeptic patients with positive serology for H. pylori confirmed by 13C urea breath test (UBT), at 0 and 2 weeks, were enrolled. Treatment consisted of one 4 mg garlic oil capsule with a meal four times per day for 14 days. H. pylori eradication was defined as a negative UBT at both follow-up appointments. Suppression was defined as a 50% fall in 13C excess between baseline and follow-up 1.
RESULTS: Five patients completed the study. There was no evidence of either eradication or suppression of H. pylori or symptom improvement whilst taking garlic oil.
CONCLUSION: These negative results show that, within the gastric milieu, garlic oil at this dose does not inhibit H. pylori. A higher dose administered for a longer time-period may be effective. Antibiotics are usually combined with a proton-pump inhibitor or bismuth salt, as the only antibiotic with any in vivo activity against H. pylori in monotherapy is clarithromycin. A proton pump inhibitor raises gastric pH and, by increasing bacterial division, may increase the in vivo activity of garlic oil. This may be worth pursuing in a future trial.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683929     DOI: 10.1046/j.1523-5378.2001.00036.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  9 in total

Review 1.  Non-pharmacological treatment of Helicobacter pylori.

Authors:  Haim Shmuely; Noam Domniz; Jacob Yahav
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

Review 2.  Allicin in Digestive System Cancer: From Biological Effects to Clinical Treatment.

Authors:  Yang Zhou; Xingxuan Li; Wenyu Luo; Junfeng Zhu; Jingwen Zhao; Mengyao Wang; Lixuan Sang; Bing Chang; Bingyuan Wang
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

Review 3.  Exploring alternative treatments for Helicobacter pylori infection.

Authors:  Guadalupe Ayala; Wendy Itzel Escobedo-Hinojosa; Carlos Felipe de la Cruz-Herrera; Irma Romero
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

4.  Essential oils as components of a diet-based approach to management of Helicobacter infection.

Authors:  G E Bergonzelli; D Donnicola; N Porta; I E Corthésy-Theulaz
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

5.  Efficacy of sulforaphane in eradicating Helicobacter pylori in human gastric xenografts implanted in nude mice.

Authors:  Xavier Haristoy; Karine Angioi-Duprez; Adrien Duprez; Alain Lozniewski
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

Review 6.  The role of herbs and spices in cancer prevention.

Authors:  Christine M Kaefer; John A Milner
Journal:  J Nutr Biochem       Date:  2008-06       Impact factor: 6.048

7.  Assessment of antibacterial effect of garlic in patients infected with Helicobacter pylori using urease breath test.

Authors:  Mahmoud Zardast; Kokab Namakin; Jamil Esmaelian Kaho; Sarira Sadat Hashemi
Journal:  Avicenna J Phytomed       Date:  2016 Sep-Oct

Review 8.  A Comprehensive Review of the Role of Complementary and Dietary Medicines in Eradicating Helicobacter pylori.

Authors:  Saeed Abdi; Sara Ataei; Maede Abroon; Pantea Majma Sanaye; Mohammad Abbasinazari; Amir Farrokhian
Journal:  Iran J Pharm Res       Date:  2022-06-18       Impact factor: 1.962

9.  Allicin as add-on therapy for Helicobacter pylori infection: A systematic review and meta-analysis.

Authors:  Xiao-Bei Si; Xu-Min Zhang; Shuai Wang; Yu Lan; Shuo Zhang; Lin-Yu Huo
Journal:  World J Gastroenterol       Date:  2019-10-21       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.